📰 Afmd News
Page 6 - Afmd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Afmd. Real-time updates on events, politics, business and more.
May 25, 2022
Brokerages expect that Affimed (NASDAQ:AFMD – Get Rating) will post sales of $9.93 million for the current quarter, Zacks reports. Five analysts have provided estimates for Affimed’s earnings, with estimates ranging from $4.42 million to $13.82 million. Affimed posted sales of $14.05 million during the same quarter last year, which suggests a negative year over […]
May 4, 2022
Equities research analysts predict that Affimed (NASDAQ:AFMD – Get Rating) will post sales of $9.93 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Affimed’s earnings, with the highest sales estimate coming in at $13.82 million and the lowest estimate coming in at $4.42 million. Affimed posted sales of […]
May 1, 2022
Affimed (NASDAQ:AFMD – Get Rating) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 6,560,000 shares, an increase of 39.3% from the March 31st total of 4,710,000 shares. Based on an average trading volume of 1,720,000 shares, the days-to-cover ratio […]
April 29, 2022
Affimed (NASDAQ:AFMD – Get Rating) – Stock analysts at SVB Leerink reduced their FY2025 earnings per share estimates for Affimed in a report issued on Wednesday, April 27th. SVB Leerink analyst D. Graybosch now expects that the biopharmaceutical company will post earnings of $0.15 per share for the year, down from their prior estimate of […]
April 18, 2022
Affimed (NASDAQ:AFMD – Get Rating) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 4,710,000 shares, a growth of 27.0% from the March 15th total of 3,710,000 shares. Currently, 4.3% of the shares of the company are short sold. Based […]
April 14, 2022
Wall Street brokerages forecast that Affimed (NASDAQ:AFMD – Get Rating) will announce ($0.21) earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Affimed’s earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.24). Affimed posted earnings per share of $0.01 during the same quarter last […]
April 13, 2022
Analysts predict that Affimed (NASDAQ:AFMD – Get Rating) will report sales of $9.42 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Affimed’s earnings, with the lowest sales estimate coming in at $4.42 million and the highest estimate coming in at $13.82 million. Affimed posted sales of $14.05 million […]
April 2, 2022
Affimed (NASDAQ:AFMD – Get Rating) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02), Fidelity Earnings reports. Affimed had a negative net margin of 132.18% and a negative return on equity of 40.23%. During the same quarter in […]
March 1, 2022
Wall Street brokerages expect Affimed (NASDAQ:AFMD – Get Rating) to announce earnings per share of ($0.17) for the current quarter, according to Zacks. Four analysts have made estimates for Affimed’s earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.23). Affimed reported earnings per share of ($0.20) during the same quarter last year, […]